Sentry Investment Management LLC Has $135,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Sentry Investment Management LLC decreased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 14.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 685 shares of the medical research company’s stock after selling 112 shares during the period. Sentry Investment Management LLC’s holdings in IQVIA were worth $135,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. FMR LLC increased its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA in the third quarter valued at about $147,683,000. JPMorgan Chase & Co. boosted its position in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB boosted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of IQVIA by 68.5% during the 4th quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock valued at $121,109,000 after purchasing an additional 250,458 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $190.77 on Thursday. The company has a market cap of $33.59 billion, a PE ratio of 25.44, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The business has a 50 day moving average price of $199.40 and a 200-day moving average price of $215.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on IQV. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. The Goldman Sachs Group cut their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Morgan Stanley upped their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Finally, Bank of America cut their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

Insider Activity at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.